Genetic discovery could improve treatment of colorectal cancer

by Rémi Carlier,Ecole Polytechnique Federale de LausannePOU5F1B differs from OCT4. a Representative immunofluorescence–confocal microscopy of POU5F1B-HA overexpressing SW480 cells, with DAPI in

Updated on: December 25,2023 10

Genetic discovery could improve treatment of colorectal cancer

by Rémi Carlier,Ecole Polytechnique Federale de LausannePOU5F1B differs from OCT4. a Representative immunofluorescence–confocal microscopy of POU5F1B-HA overexpressing SW480 cells, with DAPI in

Updated on:December 25,2023 10

Endocrine disruptors may increase risk of endometrial cancer

by University of GranadaTable full of cosmetic products. Credit: University Of GranadaResearchpublishedin the journalEnvironmental Health Perspectives, has revealed a link betwe

Updated on: March 20,2024 20

Endocrine disruptors may increase risk of endometrial cancer

by University of GranadaTable full of cosmetic products. Credit: University Of GranadaResearchpublishedin the journalEnvironmental Health Perspectives, has revealed a link betwe

Updated on:March 20,2024 20

Researchers reveal most common complications associated with cancer in pregnant women

by Keele UniversityCredit:Mayo Clinic Proceedings(2021). DOI: 10.1016/j.mayocp.2021.03.038A study led by Keele University aims to improve outcomes for pregnant women who are at a high

Updated on: May 23,2024 7

Researchers reveal most common complications associated with cancer in pregnant women

by Keele UniversityCredit:Mayo Clinic Proceedings(2021). DOI: 10.1016/j.mayocp.2021.03.038A study led by Keele University aims to improve outcomes for pregnant women who are at a high

Updated on:May 23,2024 7

Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients

byH. Lee Moffitt Cancer Center & Research InstituteHemoglobin changes from baseline over time on treatment with magrolimab + azacitidine in patients with HR-MDS (N = 95). Data shown are medi

Updated on: December 28,2023 9

Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients

byH. Lee Moffitt Cancer Center & Research InstituteHemoglobin changes from baseline over time on treatment with magrolimab + azacitidine in patients with HR-MDS (N = 95). Data shown are medi

Updated on:December 28,2023 9

Tiny surgical robots could transform detection and treatment of cancers

byUniversity of LeedsRobotic platform for peripheral lung tumor intervention based on magnetic tentacles. Credit: STORM Lab, University of LeedsA tiny robot which can travel deep into the lungs

Updated on: January 08,2024 12

Tiny surgical robots could transform detection and treatment of cancers

byUniversity of LeedsRobotic platform for peripheral lung tumor intervention based on magnetic tentacles. Credit: STORM Lab, University of LeedsA tiny robot which can travel deep into the lungs

Updated on:January 08,2024 12

New wireless device can aid recovery of breast cancer patients

byEngineering and Physical Sciences Research CouncilMammograms showing a normal breast (left) and a cancerous breast (right). Credit: Wikipedia.Patient studies of a new sensing device have prove

Updated on: December 18,2023 19

New wireless device can aid recovery of breast cancer patients

byEngineering and Physical Sciences Research CouncilMammograms showing a normal breast (left) and a cancerous breast (right). Credit: Wikipedia.Patient studies of a new sensing device have prove

Updated on:December 18,2023 19

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on: April 28,2024 0

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on:April 28,2024 0

Comparison of FDG-PET/CT and CT for treatment evaluation of patients with unresectable malignant pleural mesothelioma

by Impact Journals LLCEpithelioid MPM, stage IIIB (cT4N0M0), woman, 64 years old. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28594A new research paper titled "Comparison of FDG

Updated on: July 17,2024 0

Comparison of FDG-PET/CT and CT for treatment evaluation of patients with unresectable malignant pleural mesothelioma

by Impact Journals LLCEpithelioid MPM, stage IIIB (cT4N0M0), woman, 64 years old. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28594A new research paper titled "Comparison of FDG

Updated on:July 17,2024 0

Pictures of Melanoma and Other Skin Cancers

Pictures of Melanoma and Other Skin CancersSkin cancer pictures can help you spot abnormalities that warrant evaluationByAngelica BottaroUpdated on October 28, 2023Medically reviewed

Updated on: January 28,2024 0

Pictures of Melanoma and Other Skin Cancers

Pictures of Melanoma and Other Skin CancersSkin cancer pictures can help you spot abnormalities that warrant evaluationByAngelica BottaroUpdated on October 28, 2023Medically reviewed

Updated on:January 28,2024 0

Lazarus effect in a patient treated with osimertinib for non-small cell lung cancer with leptomeningeal disease

by Impact Journals LLCTreatment timeline with chest computed tomography (CT) and brain magnetic resonance images (MRI) on osimertinib. (A) Pretreatment CT chest, demonstrating 18 mm spiculated mass in

Updated on: March 24,2024 15

Lazarus effect in a patient treated with osimertinib for non-small cell lung cancer with leptomeningeal disease

by Impact Journals LLCTreatment timeline with chest computed tomography (CT) and brain magnetic resonance images (MRI) on osimertinib. (A) Pretreatment CT chest, demonstrating 18 mm spiculated mass in

Updated on:March 24,2024 15

Guideline updated for initial management of advanced prostate cancer

by Elana GotkineFor patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen depri

Updated on: January 08,2024 10

Guideline updated for initial management of advanced prostate cancer

by Elana GotkineFor patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen depri

Updated on:January 08,2024 10

Endometrial cancer: New insights into a deadly disparity

byMemorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainEndometrial cancer—which develops in the lining of the uterus (womb) and is sometimes called uterine cancer—is on the ris

Updated on: December 28,2023 6

Endometrial cancer: New insights into a deadly disparity

byMemorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainEndometrial cancer—which develops in the lining of the uterus (womb) and is sometimes called uterine cancer—is on the ris

Updated on:December 28,2023 6